secwatch.observer — SEC 8-K summary
======================================

Issuer:     Orgenesis Inc. (—)
CIK:        0001460602
Form:       8-K
Filed at:   2023-03-31T23:59:59+00:00
Accession:  0001493152-23-010046
Event type: debt
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 2.03, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Orgenesis subsidiary Koligo enters $5M convertible loan with Yehuda Nir at 8% interest
--------------------------------------------------------------------------------

- Loan up to $5M from lender Yehuda Nir to subsidiary Koligo Therapeutics; 8% annual interest, maturity Jan 1, 2024.
- Mandatory conversion at 50% discount per share if Koligo completes a qualified equity financing of at least $5M by Dec 31, 2023.
- Lender may assign $1.5M of existing Orgenesis loan to Koligo under original terms (10% interest, maturity Jan 31, 2026).
- Proceeds to be used for working capital; events of default include bankruptcy, material breach, and payment failure.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1460602/000149315223010046/0001493152-23-010046-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1460602/000149315223010046/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-010046

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer